Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
Prof. Patrick Tschopp, University of Basel
Abstract (lay summary see below)
Chronic or acute diseases affecting the neuromuscular system can cause debilitating symptoms in
human patients, yet they may manifest through very different etiologies. For example, either muscle or
nerve tissue can present the primary pathological phenotype. However, the intricate functional connection between the two tissues, through so-called neuromuscular circuits, will eventually result in deficiencies in both, if disease is allowed to progress unchecked. Correct embryonic assembly of these neuromuscular circuits is essential, in order to ensure faithful muscle-nerve communication. The required circuit specificity is determined – at least in part – by molecularly defined subgroups of motor neurons, so-called motor neuron «pools». Neurons of a given pool project their axons to a single muscle in the periphery. Whether or not distinct molecular subtypes also exist among the various muscle groups is currently less clear. We know, however, that both antero- and retrograde signals between muscle fibers and motor neurons play a crucial role in refining these circuits during development, and maintaining robustness and functionality during homeostasis.
The goal of this proposal is thus to profile molecular signatures of circuit-specific muscle and motor neuron pairs, and to functionally test their relevance in neuromuscular circuit formation. For this, I propose to combine state-of-the-art single-cell RNA-sequencing of axon-backfilled motor neurons with bulk transcriptomic analyses of micro-dissected limb muscles connected to the corresponding motor neuron pools. Furthermore, we will exploit a unique experimental setting, in which one of the main motor nerve branches is re-routed and ectopically connects to a duplicated muscle, thereby shunting the original circuit logic. We will evaluate the role of emerging candidate genes using gain- and loss-offunction approaches in both muscle- and neuron-lineages.
A better understanding of the molecular crosstalk between muscle and motor neurons will provide new insights into the mechanisms of neuromuscular circuit formation, refinement and maintenance, as well as support the development of regenerative therapies for treating human muscle and nerve diseases.
***********
preliminary data and analyses for this proposal were generated with the help of Dr. Maëva Luxey, Bianka Berki and Fabio Sacher
Lay summary
Arme und Beine werden durch die Kontraktion peripherer Muskeln bewegt. Die Kontraktionsmuster
werden im zentralen Nervensystem generiert, und durch sogenannte neuromuskuläre Schaltkreise an
die Muskeln weitergeleitet. Gleichzeitig bedarf es dieser Schaltkreise auch um essenzielle Botenstoffen
zwischen Muskeln und Nerven auszutauschen – tritt eine Erkrankung in einem Gewebe auf, nimmt
auch das andere längerfristig Schaden.
Während der embryonalen Entwicklung müssen diese Schaltkreise mit höchster Präzision erstellt
werden, um eine korrekte Kommunikation zwischen Muskeln und Nerven zu gewährleisten. Diese
Präzision beruht – zumindest teilweise – auf molekular definierten Nervenzell-Subtypen, die jeweils
nur einen einzelnen Muskel kontaktieren. Ob ähnliche molekulare Subtypen bei Muskeln existieren,
und welche Wechselwirkungen in spezifischen Muskel/Nerv-Paaren auftreten, ist zurzeit unklar.
Im vorliegenden Forschungsprojekt planen wir daher die molekulare Schaltkreis-Logik von
einzelnen Nervenzell-Subtypen und ihren verbundenen Muskeln zu entschlüsseln. Wir erhoffen uns
dadurch neue Einblicke in die Entwicklung und Instandhaltung neuromuskulärer Schaltkreise, sowie
regenerativ-therapeutische Ansätze zur Behandlung von Muskel- und Nerven-Erkrankungen.
Projekte
- Neue Forschungsprojekte ab 2024
- Die Bedeutung und die Erfolge der Forschung
- Finanzierte Projekte
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Projektbroschüre
- SEAL Therapeutics AG
- Meetings und Seminare
- Teilnahme an Dachverbände
- Patientenregister
- Netzwerk Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch